Evaluating the Risk of Postoperative Venous Thromboembolism in Cervical Cancer Patients
Development and Validation of Machine Learning Models to Evaluate the Postoperative Venous Thromboembolism Risk of Cervical Cancer Patients in China
1 other identifier
observational
1,174
1 country
1
Brief Summary
The aim of this study is to develop a machine learning model to accurately predict the risk of venous thromboembolism in patients with cervical cancer after surgery.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2019
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2023
CompletedFirst Submitted
Initial submission to the registry
August 6, 2024
CompletedFirst Posted
Study publicly available on registry
August 16, 2024
CompletedAugust 16, 2024
August 1, 2024
5 years
August 6, 2024
August 15, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Whether the patient has developed VTE is determined based on the diagnostic criteria in the "Guidelines for the Prevention and Treatment of Tumor-Associated Venous Thromboembolism (2019 Edition)."
The diagnosis of VTE primarily includes the diagnosis of DVT and PE. According to the guidelines, DVT is diagnosed using venous compression ultrasound or venography, while PE is diagnosed using CT pulmonary angiography (CTPA) or nuclear lung ventilation/perfusion imaging.
December 31, 2023
Eligibility Criteria
Our data was collected from electronic case of the cervical cancer patients who underwent surgical treatment at the Cancer Hospital affiliated with Chongqing University between January 2019 and December 2022
You may qualify if:
- Confirmation of cervical cancer through pathological examination.
- Receipt of surgical treatment for cervical cancer at Chongqing University Cancer Hospital in China.
- Provision of comprehensive case information.
You may not qualify if:
- Patients under the age of 18.
- History of VTE caused by other reasons before surgery.
- Secondary cervical cancer or accompanying primary malignant tumor.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Haike Leilead
Study Sites (1)
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, 400030, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- director
Study Record Dates
First Submitted
August 6, 2024
First Posted
August 16, 2024
Study Start
January 1, 2019
Primary Completion
December 31, 2023
Study Completion
December 31, 2023
Last Updated
August 16, 2024
Record last verified: 2024-08